SWX:NOVNPharmaceuticals
Novartis (SWX:NOVN) Valuation Check After Vanrafia Phase III ALIGN Results Spark Investor Interest
Why the Vanrafia trial is moving Novartis shares
Novartis (SWX:NOVN) is back in focus after final Phase III ALIGN data showed its drug Vanrafia slowed kidney function decline in adults with IgA nephropathy, reinforcing earlier approvals and helping spark fresh investor interest.
See our latest analysis for Novartis.
The Vanrafia update lands on top of a strong run for Novartis, with a 30 day share price return of 8.25% and a 90 day share price return of 18.30%. This has contributed to a 1...